In today’s briefing:
- SCLX: Revenues Beat Estimates in 2Q
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
SCLX: Revenues Beat Estimates in 2Q
- SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.
- The company already has commercialized products that are proven to improve patients’ lives.
- The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.